Confronto

Glepaglutide vs. Selank

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

nessun dato

129954-34-3

Peso molecolare

nessun dato

751.85 g/mol

Emivita

nessun dato

0.3 h

Sequenza

nessun dato

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Meccanismo d'azione

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Selank

Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Glepaglutide	Selank
Germania	Non approvato	Non approvato
RU	—	Su prescrizione
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between Glepaglutide and Selank?: Glepaglutide is classified as "Ricerca (altro)", while Selank is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Selank?: The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "Studio sull'uomo" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Selank in Germany and the United States?: Germania: Glepaglutide — Non approvato, Selank — Non approvato. Stati Uniti: Glepaglutide — Non approvato, Selank — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Selank

Germania

Non approvato

—

Su prescrizione

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Glepaglutide and Selank?

Glepaglutide is classified as "Ricerca (altro)", while Selank is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Selank?

The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "Studio sull'uomo" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Selank in Germany and the United States?

Germania: Glepaglutide — Non approvato, Selank — Non approvato. Stati Uniti: Glepaglutide — Non approvato, Selank — Non approvato. These are factual summaries with source and review date on the individual pages.